Opendata, web and dolomites


A minimally invasive, outpatient treatment for Gastroesophageal Reflux Disease (GERD), resulting in permanent relief from both GERD symptoms and life-long drug dependency

Total Cost €


EC-Contrib. €






 G125 project word cloud

Explore the words cloud of the G125 project. It provides you a very rough idea of what is the project "G125" about.

gastro    supply    prepare    gastric    underlying    sphincter    thereby    fibro    bulking    barrier    injectable    intervention    lower    pmma    gastroenterological    ascentx    digestive    transition    agent    ppis    caused    root    reflux    anti    area    plan    unfortunately    biocompatible    least    made    medications    regurgitation    uses    microspheres    collagen    commercialization    medical    heartburn    stimulated    les    normal    market    gastroesophageal    injection    needle    union    treatment    bovine    15    disease    responders    syringe    invasive    g125    pump    flexible    esophagal    symptoms    consists    refine    elongated    catheter    12    cell    cure    option    medication    permanent    severe    followed    daily    diagnosis    inhibitors    endoscopic    million    suspended    treat    surgical    disorder    content    efs    ingrowth    outpatient    bore    trial    mask    20    procedure    people    proton    debilitating    integrity    sufferers    perform    innovation    vascular    drafted    scaffold    clinical    acid    enzymes    esophageal    chain    tissue    gerd    polymethylmethcrylate    patients    strategy   

Project "G125" data sheet

The following table provides information about the project.


Organization address
city: LONDON
postcode: E95EN
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-09-01   to  2019-12-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 


 Project objective

Gastroesophageal Reflux Disease (GERD) is a digestive disorder associated with symptoms such as heartburn and regurgitation, and reflux of normal gastric content like gastric acid and digestive enzymes. GERD is caused by a loss of integrity of the gastro-esophageal barrier known as the 'lower esophageal sphincter' (LES). This condition is one of the most common gastroenterological diagnosis in the European Union, with an estimated 15-20 Million daily sufferers. GERD today is typically treated with medications such as proton pump inhibitors (PPIs). Unfortunately, these anti-acid medications only ‘mask’ GERD symptoms, cause severe side-effects long-term, and about 20% of patients are non-responders. Importantly, they do not treat/cure the underlying root cause of acid reflux. For people who have severe GERD and do not respond to medication, invasive surgical intervention remains the only option. G125 is the least invasive outpatient treatment for Gastroesophageal Reflux Disease (GERD). It is a permanent injectable bulking agent for the endoscopic treatment which enables cell growth in the Lower Esophagal Sphincter (LES), thereby providing long term cure for the debilitating symptoms of GERD. G125 uses a tissue-friendly (biocompatible) microspheres made of Polymethylmethcrylate (PMMA) suspended in bovine collagen and an Elongated Flexible Syringe (EFS) which consists of an elongated catheter and a transition bore needle. The PMMA microspheres provide a permanent scaffold for stimulated fibro-vascular tissue ingrowth in the affected area. During the phase 1 project, a go-to-market strategy and a supply chain will be established, as well as further development plan will be drafted. Within the overall innovation project AscentX Medical will refine the endoscopic injection procedure, perform a 12 month clinical trial with 60 patients followed by a scale up of the production to prepare for commercialization.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "G125" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "G125" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More